Table 3.

Application of the proposed spectrophotometric methods for the determination of BAC in commercial tablets.

Mylobac® tablets	(Method I)	(Method II)	(Method III)	Reported method [29]
%Found ±SD∗	97.50 ± 0.26	97.91 ± 1.20	97.47 ± 0.72	97.05 ± 0.48
RSD%	0.27	1.23	0.74	0.49

ANOVA (single factor)
Source of Variation	SS	df	MS	F	P-value	F critical
Between Groups	1.825975	3	0.608658	1.08756	0.382722	3.238872
Within Groups	8.95448	16	0.559655
Total	10.78046	19

Baclofen® tablets	(Method I)	(Method II)	(Method III)	Reported method [29]
%Found ±SD∗	99.37 ± 0.57	98.94 ± 0.41	98.55 ± 1.30	98.64 ± 0.92
RSD%	0.57	0.41	1.32	0.93

ANOVA (single factor)
Source of Variation	SS	df	MS	F	P-value	F critical
Between Groups	2.026095	3	0.675365	0.893133	0.466005	3.238872
Within Groups	12.0988	16	0.756175
Total	14.1249	19

^∗Mean ± standard deviation for five determinations.